empagliflozin/metformin/sitagliptin (CKD-379) / Chong Kun Dang - LARVOL DELTA

Real-World Preference for Triple Fixed-Dose Combination of Empagliflozin, Sitagliptin, and Metformin by Various Health Care Specialist in India: Real Impossible Trio (ADA 2026) - "In Indian outpatient practice, empagliflozin sitagliptin metformin FDC utilized by across specialties. Dosage selection appears to be influenced by specific medical specialty and nature of patient's cardiovascular comorbidities."

Clinical • Real-world • Real-world evidence • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluating the Frequency of Vitamin B12 Assays in Persons with Type 2 Diabetes Using Metformin: A Retrospective Analysis (AACE 2026) - "Metformin was the most frequently prescribed therapy, with 95.5% receiving metformin monotherapy, while combination regimens such as metformin/sitagliptin, metformin/empagliflozin, and metformin/dapagliflozin were uncommon. Higher testing rates were observed among patients aged 30–49, females, and those with documented neuropathy; however, overall screening remained variable across groups. Patients"

Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes (clinicaltrials.gov) - P4 | N=186 | Completed | Sponsor: Hawler Medical University

New P4 trial • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • RETN

Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes (clinicaltrials.gov) - P4 | N=110 | Enrolling by invitation | Sponsor: Bahria University

New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double-blind, multicentre, therapeutic confirmatory phase 3 clinical trial. (PubMed, Diabetes Obes Metab) - "These results suggest that coadministration of empagliflozin safely improves glycemic control in Korean patients with T2DM uncontrolled by sitagliptin and metformin."

Journal • P3 data • Diabetes • Metabolic Disorders • Renal Disease • Type 2 Diabetes Mellitus

Not All That Glitters Is Diabetes: When Diabetes Glomerulopathy Was Not the Only Answer, a Case Series (KIDNEY WEEK 2025) - "Medications Valsartan, empagliflozin, Sitagliptin/Metformin, Nifedipine...Medications: Valsartan + HCT, NPH insulin, Oxcarbazepine, Hb 7.6, creatinine 5.8, A1c 9.1...Discussion These three different patients with poorly controlled diabetes showed that in some cases it is crucial to perform kidney biopsy since other pathologies could be contributing or causing kidney damage. Although diabetic nephropathy remains the leading cause of end-stage renal disease, it is often assumed without confirmation, which can lead to missed or delayed diagnoses."

Clinical • Amyloidosis • Anemia • Back Pain • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Glomerulonephritis • Hematological Disorders • Hematological Malignancies • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • Lupus Nephritis • Lymphoma • Metabolic Disorders • Musculoskeletal Pain • Nephrology • Non-Hodgkin’s Lymphoma • Renal Disease

Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P3 | N=50 | Completed | Sponsor: University of Lahore

New P3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Chong Kun Dang wins Korean nod for diabetes combo as rivals crowd in (Korea Biomedical Review) - "Chong Kun Dang (CKD) has pulled ahead in Korea’s diabetes race with the country’s first approval of a fixed-dose combo pairing SGLT2 inhibitor empagliflozin and DPP-4 inhibitor sitagliptin. On Monday, the Ministry of Food and Drug Safety cleared Empamax S in two strengths—25/100 mg and 10/100 mg—for adults with type 2 diabetes who need dual therapy. CKD filed for approval in May 2024 and landed the nod less than a year later, setting up a domestic launch in November 2025....The win puts CKD ahead of at least eight competitors with similar combinations in development, including two empagliflozin-sitagliptin duals and six triple combos that add metformin to the mix."

Korea approval • Launch non-US • Type 2 Diabetes Mellitus

A Clinical Trial to Evaluate the Food Effect of CKD-379 (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Clinical Trial to Evaluate the Food Effect of CKD-379 (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379 (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Study to Evaluate the Safety and Pharmacokinetics of CKD-379 (clinicaltrials.gov) - P1 | N=32 | Active, not recruiting | Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Pharmacokinetics and Safety/Tolerability of CKD-379 (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Pharmacokinetics and Safety/Tolerability of CKD-379 (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Pharmacokinetics and Safety/Tolerability Profile of CKD-379 (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Pharmacokinetics and Safety/Tolerability Profile of CKD-379 (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus